Sands Capital Ventures’s Taysha Gene Therapies TSHA Stock Holding History

Sands Capital Ventures’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.53M	Hold	724,873	–	–	0.51%	24
2026 Q2	$4.94M	Hold	724,873	–	–	0.8%	21
2026 Q1	$3.24M	Hold	724,873	–	–	0.77%	17
2025 Q4	$3.99M	Hold	724,873	–	–	0.77%	18
2025 Q3	$2.37M	Hold	724,873	–	–	0.52%	18
2025 Q2	$1.67M	Hold	724,873	–	–	0.33%	19
2025 Q1	$1.01M	Hold	724,873	–	–	0.25%	20
2024 Q4	$1.25M	Hold	724,873	–	–	0.27%	19
2024 Q3	$1.46M	Hold	724,873	–	–	0.41%	12
2024 Q2	$1.62M	Hold	724,873	–	–	0.54%	11
2024 Q1	$2.08M	Hold	724,873	–	–	0.5%	10
2023 Q4	$1.28M	Hold	724,873	–	–	0.36%	13
2023 Q3	$2.29M	Hold	724,873	–	–	0.68%	13
2023 Q2	$478K	Hold	724,873	–	–	0.14%	14
2023 Q1	$580K	Hold	724,873	–	–	0.14%	16
2022 Q4	$1.64M	Hold	724,873	–	–	0.45%	15
2022 Q3	$1.4M	Hold	724,873	–	–	0.41%	16
2022 Q2	$2.7M	Hold	724,873	–	–	0.74%	16
2022 Q1	$4.73M	Hold	724,873	–	–	0.99%	13
2021 Q4	$8.44M	Hold	724,873	–	–	1.25%	11
2021 Q3	$13.5M	Buy	+724,873	New	+$13.8M	2.04%	7

Other funds holding TSHA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sands Capital Ventures's TSHA Position: Q3 2026 in Review

Sands Capital Ventures held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 724,873 shares worth $3.53M. The position accounts for 0.51% of the portfolio, ranked #24.

Sands Capital Ventures first reported a position in TSHA in Q3 2021 and has held it in 21 quarters since. The position peaked at $13.5M in Q3 2021. 135 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Sands Capital Ventures held 724,873 shares of Taysha Gene Therapies worth $3.53M as of Q3 2026.
Sands Capital Ventures left its Taysha Gene Therapies share count unchanged in Q3 2026.
Taysha Gene Therapies made up 0.51% of Sands Capital Ventures's portfolio in Q3 2026, its #24 holding.
Sands Capital Ventures first reported a position in Taysha Gene Therapies in Q3 2021 and has held it in 21 quarters since.
Sands Capital Ventures's Taysha Gene Therapies position peaked at $13.5M in Q3 2021.
135 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Sands Capital Ventures's 13F filing for Q3 2026, filed 13 Nov 2026.